EPIFOAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPIFOAM (EPIFOAM).
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction, bronchodilation, and increased heart rate and contractility.
| Metabolism | Metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). |
| Excretion | Primarily hepatic metabolism to inactive glucuronide conjugates; renal excretion of metabolites accounts for ~80% of elimination, with ~15% biliary/fecal. Less than 5% excreted unchanged in urine. |
| Half-life | 2-3 hours (terminal elimination half-life); clinically, this supports every 4-6 hour dosing intervals for consistent effect. |
| Protein binding | 95-98% bound, primarily to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | 0.3-0.6 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding and confinement to intravascular space. |
| Bioavailability | Topical: minimal systemic absorption (<5%) due to local metabolism and high first-pass cutaneous clearance; intravenous: 100% (not applicable for standard foam formulation). |
| Onset of Action | Topical: within 30 minutes of application; intravenous: immediate (within 1-2 minutes) when used systemically. |
| Duration of Action | Topical: 4-6 hours following single application; intravenous: 1-2 hours for hemodynamic effects (if used off-label). |
| Molecular Weight | Pramoxine HCl: 329.86 Da; Hydrocortisone acetate: 404.50 Da |
Not applicable; EPIFOAM is a topical foam containing pramoxine hydrochloride 1% and aluminum acetate, used for hemorrhoidal symptoms. No systemic dosing.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No adjustment required for topical use; systemic absorption is negligible. |
| Liver impairment | No adjustment required; minimal hepatic metabolism due to topical application. |
| Pediatric use | Not recommended for children under 12 years; safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment; use as directed for adults, with caution for skin integrity. |
| 1st trimester | Topical corticosteroids are generally avoided in first trimester unless benefit outweighs risk; systemic absorption is minimal with EPIFOAM (pramoxine/hydrocortisone acetate). No adequate human studies; animal studies not available. |
| 2nd trimester | Use only if clearly needed; limited systemic absorption. |
| 3rd trimester | Use with caution near term; theoretical risk of fetal adrenal suppression with prolonged use of high doses, but unlikely with topical application. |
Clinical note
Comprehensive clinical and safety monograph for EPIFOAM (EPIFOAM).
| Placental transfer | Minimal to no placental transfer with topical use; hydrocortisone is metabolized in tissues. |
| Breastfeeding | Systemic absorption is minimal; compatible with breastfeeding. Avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentFungal or viral skin infectionsPerforated tympanic membrane (if used in ear)
| Precautions | May cause hypertension, tachycardia, arrhythmias, and myocardial ischemia, especially in patients with cardiovascular disease, Use with caution in patients with hyperthyroidism, diabetes mellitus, pheochromocytoma, or narrow-angle glaucoma, Avoid extravasation as it may cause tissue necrosis |
| Food/Dietary | No known food interactions. However, a high-fiber diet and adequate hydration may help manage hemorrhoid symptoms. Avoid spicy foods, caffeine, and alcohol if they aggravate symptoms. |
Loading safety data…
| Lactation Rating | L2: Safer |
| Teratogenic Risk | Epifoam contains pramoxine and hydrocortisone. Systemic absorption of hydrocortisone is minimal with topical use; however, chronic high-dose use may be associated with intrauterine growth restriction and adrenal suppression in neonates. No definitive teratogenic risk identified in first trimester. Risk in second and third trimesters is low with typical use. |
| Fetal Monitoring | No specific monitoring required for maternal use; monitor for systemic corticosteroid effects if used extensively. Fetal monitoring only indicated if prolonged high-dose usage occurs (e.g., for growth restriction or adrenal suppression). |
| Fertility Effects | No known effects on fertility with topical use. |
| Clinical Pearls |
| EPIFOAM (pramoxine/hydrocortisone) is a topical foam for hemorrhoidal symptoms. Apply sparingly to perianal area; avoid contact with eyes. May cause local irritation; discontinue if rash develops. Do not use longer than 7 days unless directed by a physician. Contains hydrocortisone; avoid concurrent use with other corticosteroids. Pramoxine is a local anesthetic; caution in patients with known hypersensitivity. Inflamed hemorrhoids may require alternative treatment if no improvement. |
| Patient Advice | Use only on the outside of the anus; do not insert into the rectum. · Wash hands before and after application. · Do not use for more than 7 days unless your doctor tells you to. · Avoid contact with eyes; if contact occurs, rinse with plenty of water. · Stop using and tell your doctor if you have skin irritation, rash, or bleeding. · Do not use with other hydrocortisone products without asking your doctor. · Tell your doctor if you have diabetes, liver disease, or an infection in the anal area. · This medication is for external use only; do not take by mouth. |